Numbers needed to treat derived from meta-analyses - Sometimes informative, usually misleading

British Medical Journal

Volumn 318, Issue 7197, 1999, Pages 1548-1551

  Smeeth, Liam ^a   Haines, Andy ^a   Ebrahim, Shah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; FATALITY; INCIDENCE; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; RISK; TREATMENT OUTCOME;

EID: 0033062516     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.318.7197.1548     Document Type: Article

References (32)

1. 1 Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
2. 2 Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
3. 4 Review: statins prevent stroke, especially in patients with coronary heart disease. Evidence-Based Med 1998;3:10. (Abstract of: Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997;157:1305-10.)
4. 4 Review: statins prevent stroke, especially in patients with coronary heart disease. Evidence-Based Med 1998;3:10. (Abstract of: Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997;157:1305-10.)
5. 5 Egger M, Sterne JA, Davey Smith G. Meta-analysis software. 1998. www.bmj.com./archive/7126. (Cited in: Davey Smith G, Egger M. Meta-analysis. Unresolved issues and future developments. BMJ 1998;316:221-5.)
6. 6 Cochrane Database of Systematic Reviews. In: Cochrane Collaboration Cochrane Library. Issue 2. Oxford: Update Software, 1998.
7. 7 Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22
8. 8 Shepherd J, Cobbe S, Ford E, Isles C, Lorimer A, MacFarlane P, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995;333:1301-7
9. 9 4S Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
10. 10 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;14:1001-9.
11. 11 The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
12. 12 Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
13. 13 Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;XXVII:335-71
14. 14 Ebrahim S, Davey Smith G. Health promotion in older people for the prevention of coronary heart disease and stroke. London: Health Education Authority, 1996.
15. 15 Mulrow C, Lau J, Cornell J, Brand B. Antihypertensive drug therapy in the elderly. Cochrane Library. Issue 2. Oxford: Update Software, 1998.
16. 16 Office for National Statistics. Mortality statistics: cause, 1995. London: Stationary Office, 1997. (Series D112;22.)
17. 17 Cucherat M. EasyMa 1997a. Meta-analysis software. Lyons: University of Lyons, 1997.
18. 18 Statins. Bandolier January 1998;5:2-4. (www.jr2.ox.ac.uk/ bandolier/ band47/b47-2.html; accessed October 1998).
19. 19 Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317:1309-12.
20. 20 Fleiss JL. The statistical basis of meta-analysis. Stat Method Med Res 1993;2:121-45.
21. 21 Egger M, Davey Smith G, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997;315:1533-7.
22. 22 Morris S, McGuire A, Caro J, Pettitt D. Strategies for the management of hypercholesterolaemia: a systematic review of the cost-effectiveness literature. J Health Serv Res Policy 1997;2:231-50.
23. 23 Jackson RT, Sackett DL. Guidelines for managing raised blood pressure. BMJ 1996;313:64-5.
24. 24 Davey Smith G, Egger M, Phillips AN. Meta-analysis: beyond the grand mean? BMJ 1997;315:1610-4.
25. 25 Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet 1995;345:1616-9.
26. 26 Sharp SJ, Thompson SG, Altman DG. The relation between treatment benefit and underlying risk in meta-analysis. BMJ 1996;313:735-8.
27. 27 Fahey T, Griffiths S, Peters TJ. Evidence based purchasing: understanding results of clinical trials and systematic reviews. BMJ 1995;311:1056-60.
28. 28 McColl A, Smith H, White P, Field J. General practitioners' perceptions of the route to evidence based medicine: a questionnaire survey. BMJ 1998;316:361-5.
29. 29 Hux JE, Naylor CD. Communicating the benefits of chronic preventative therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decision Making 1995;15:152-7.
30. 30 Cranney M, Walley T. Same information, different decisions: the influence of evidence on the management of hypertension in the elderly. Br J Gen Pract 1996;16:661-3.
31. 31 Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992;117:916-21.
32. 32 Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C. Hypertension in the elderly. Implications and generalizability of randomized trials. JAMA 1994;272:1932-8.